# US 2019/0292179 A1 · TGF Beta RECEPTOR ANTAGONISTS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0292179 A1
- Document ID: US20190292179A1
- Status: Published application
- Kind: A1
- Application number: 16/316,714
- Filed: 2017-07-19
- Published: 2019-09-26
- Earliest claimed: 2016-07-21
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Robert M. Borzilleri; Peiyung Liu; Andrew J. Tebben; Upender Velaparthi; Hasibur Rahaman; Gopikishan Tonukunuru; Jayakumar Sankara Warrier
- Web page: https://patentgrep.com/patent/US20190292179A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 487/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

## Claims

### Claim 1

A compound having the structure of formula (Ia) or (Ib):
or a pharmaceutically acceptable salt thereof,
wherein
A is phenyl substituted with 0-3 R4 groups or pyridyl substituted with 0-3 R4 groups;
each R4 is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NO2, or —CN;
Z is a 10-12 membered heterobicyclic ring substituted with 0-2 RZ groups containing 1-4 heteroatoms selected from —O—, —S— or —N—;
each RZ is independently halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkanol, —COO C1-C6 alkyl, —CONRz1Rz2, —NHC(O) C1-C6 haloalkyl, —NHC(O) C1-C6 alkyl, or —NH C1-C6 alkyl;
each Rz1 and Rz2 is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R1 is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkanol, C1-C6 haloalkyl, C1-C6 alkyloxy, CONR1aR1b, —NHC(O) C1-C6 alkyl, —COOH or —COO C1-C6 alkyl;
each R1a and R1b is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl
R2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyloxy or C3-C8 cycloalkyl;
or R1 and R2 combined with the atoms to which they are attached form a five- to eight-membered ring.

### Claim 2 (depends on 1)

A compound according to claim 1 of formula (Ia):
or a pharmaceutically acceptable salt thereof,
wherein
A is phenyl substituted with 0-3 R4 groups or pyridyl substituted with 0-3 R4 groups;
each R4 is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NO2, or —CN;
Z is a 10-12 membered heterobicyclic ring substituted with 0-2 RZ groups containing 1-4 heteroatoms selected from —O—, —S— or —N—;
each RZ is independently halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkanol, —COO C1-C6 alkyl, —CONRz1Rz2, —NHC(O) C1-C6 haloalkyl, —NHC(O) C1-C6 alkyl, or —NH C1-C6 alkyl;
each Rz1 and Rz2 is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R1 is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkanol, C1-C6 haloalkyl, C1-C6 alkyloxy, CONR1aR1b, —NHC(O) C1-C6 alkyl, —COOH or —COO C1-C6 alkyl;
each R1a and R1b is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl
R2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyloxy or C3-C8 cycloalkyl;
or R1 and R2 combined with the atoms to which they are attached form a five- to eight-membered ring.

### Claim 3 (depends on 2)

The compound of claim 2, wherein
A is phenyl substituted with 0-2 R4 groups or pyridyl substituted with 0-2 R4 groups;
each R4 is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NO2, or —CN;
Z is a 10-12 membered heterobicyclic ring substituted with 0-2 RZ groups containing 1-4 heteroatoms selected from —O—, —S— or —N—;
each RZ is independently halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkanol, —COO C1-C6 alkyl, —CONRz1Rz2, —NHC(O) C1-C6 haloalkyl, —NHC(O) C1-C6 alkyl, or —NH C1-C6 alkyl;
each Rz1 and Rz2 is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R1 is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkanol, C1-C6 haloalkyl, C1-C6 alkyloxy, CONR1aR1b, —NHC(O) C1-C6 alkyl, —COOH or —COO C1-C6 alkyl;
each R1a and R1b is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl
R2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyloxy or C3-C8 cycloalkyl;
or R1 and R2 combined with the atoms to which they are attached form a five- to eight-membered ring.

### Claim 4 (depends on 3)

The compound according to claim 3, wherein
Z is
and n is 0, 1 or 2.

### Claim 5 (depends on 4)

The compound according to claim 4, wherein
Z is
and n is 0, 1 or 2.

### Claim 6 (depends on 4)

The compound according to claim 4, wherein
Z is
and n is 0, 1 or 2.

### Claim 7 (depends on 4)

The compound according to claim 4, wherein
Z is
and n is 0, 1 or 2.

### Claim at position 8

8-16. (canceled)

### Claim 17 (depends on 1)

The compound as defined in claim 1 of the formula
or a pharmaceutically acceptable salt thereof,
wherein
each R4 is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NO2, or —CN;
each RZ is independently halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkanol, —COO C1-C6 alkyl, —CONRz1Rz2, —NHC(O) C1-C6 haloalkyl, —NHC(O) C1-C6 alkyl, or —NH C1-C6 alkyl;
each Rz1 and Rz2 is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R1 is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkanol, C1-C6 haloalkyl, C1-C6 alkyloxy, CONR1aR1b, —NHC(O) C1-C6 alkyl, —COOH or —COO C1-C6 alkyl;
each R1a and R1b is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl
R2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyloxy or C3-C8 cycloalkyl;
or R1 and R2 combined with the atoms to which they are attached form a five- to eight-membered ring.

### Claim 18 (depends on 1)

The compound as defined in claim 1 of the formula
or a pharmaceutically acceptable salt thereof,
wherein
each R4 is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NO2, or —CN;
each RZ is independently halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkanol, —COO C1-C6 alkyl, —CONRz1Rz2, —NHC(O) C1-C6 haloalkyl, —NHC(O) C1-C6 alkyl, or —NH C1-C6 alkyl;
each Rz1 and Rz2 is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R1 is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkanol, C1-C6 haloalkyl, C1-C6 alkyloxy, CONR1aR1b, —NHC(O) C1-C6 alkyl, —COOH or —COO C1-C6 alkyl;
each R1a and R1b is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl
R2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyloxy or C3-C8 cycloalkyl;
or R1 and R2 combined with the atoms to which they are attached form a five- to eight-membered ring.

### Claim 19 (depends on 1)

A compound as defined in claim 1 of the formula
or a pharmaceutically acceptable salt thereof,
wherein
each R4 is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NO2, or —CN;
each RZ is independently halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkanol, —COO C1-C6 alkyl, —CONRz1Rz2, —NHC(O) C1-C6 haloalkyl, —NHC(O) C1-C6 alkyl, or —NH C1-C6 alkyl;
each Rz1 and Rz2 is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R1 is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkanol, C1-C6 haloalkyl, C1-C6 alkyloxy, CONR1aR1b, —NHC(O) C1-C6 alkyl, —COOH or —COO C1-C6 alkyl;
each R1a and R1b is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl
R2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyloxy or C3-C8 cycloalkyl;
or R1 and R2 combined with the atoms to which they are attached form a five- to eight-membered ring.

### Claim 20 (depends on 1)

The compound as defined in claim 1 of the formula
or a pharmaceutically acceptable salt thereof,
wherein
each R4 is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NO2, or —CN;
each RZ is independently halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkanol, —COO C1-C6 alkyl, —CONRz1Rz2, —NHC(O) C1-C6 haloalkyl, —NHC(O) C1-C6 alkyl, or —NH C1-C6 alkyl;
each Rz1 and Rz2 is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R1 is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkanol, C1-C6 haloalkyl, C1-C6 alkyloxy, CONR1aR1b, —NHC(O) C1-C6 alkyl, —COOH or —COO C1-C6 alkyl;
each R1a and R1b is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl
R2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyloxy or C3-C8 cycloalkyl;
or R1 and R2 combined with the atoms to which they are attached form a five- to eight-membered ring.

### Claim 21 (depends on 1)

The compound as defined in claim 1 of the formula
or a pharmaceutically acceptable salt thereof,
wherein
each R4 is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NO2, or —CN;
each RZ is independently halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkanol, —COO C1-C6 alkyl, —CONRz1Rz2, —NHC(O) C1-C6 haloalkyl, —NHC(O) C1-C6 alkyl, or —NH C1-C6 alkyl;
each Rz1 and Rz2 is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R1 is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkanol, C1-C6 haloalkyl, C1-C6 alkyloxy, CONR1aR1b, —NHC(O) C1-C6 alkyl, —COOH or —COO C1-C6 alkyl;
each R1a and R1b is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl
R2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyloxy or C3-C8 cycloalkyl;
or R1 and R2 combined with the atoms to which they are attached form a five- to eight-membered ring.

### Claim 22 (depends on 1)

A compound as defined in claim 1 of the formula
or a pharmaceutically acceptable salt thereof,
wherein
each R4 is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, —NO2, or —CN;
each RZ is independently halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkanol, —COO C1-C6 alkyl, —CONRz1Rz2, —NHC(O) C1-C6 haloalkyl, —NHC(O) C1-C6 alkyl, or —NH C1-C6 alkyl;
each Rz1 and Rz2 is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
R1 is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkanol, C1-C6 haloalkyl, C1-C6 alkyloxy, CONR1aR1b, —NHC(O) C1-C6 alkyl, —COOH or —COO C1-C6 alkyl;
each R1a and R1b is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl
R2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyloxy or C3-C8 cycloalkyl;
or R1 and R2 combined with the atoms to which they are attached form a five- to eight-membered ring.

### Claim 23 (depends on 1)

A pharmaceutical composition which comprises a compound according to claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 1)

A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of diseases or conditions for which a TGFβR antagonist is indicated.

### Claim 27 (depends on 26)

A compound or a pharmaceutically acceptable salt thereof for use according to claim 26, wherein the disease or condition is cancer.

### Claim 28 (depends on 27)

The use according to claim 27 wherein the cancer is small cell lung cancer, non-small cell lung cancer, triple-negative breast cancer, ovarian cancer, colorectal cancer, prostate cancer, melanoma, pancreatic cancer, multiple myeloma, T-acute lymphoblastic leukemia or AML.

### Claim at position 21

29-33. (canceled)

### Claim 34 (depends on 1)

A method for treating a subject afflicted with cancer comprising administering to the subject a therapeutically effective amount of:
a) a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and
b) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity.

### Claim 35 (depends on 34)

The method of claim 34, wherein the anti-PD-1 antibody is nivolumab.
